Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Adcetris (brentuximab vedotin)
pCPA File Number:
21110
Negotiation Status:
Negotiations were not pursued
Indication(s):
Hodgkin's Lymphoma
Sponsor/Manufacturer:
Seattle Genetics Inc.
CADTH Project Number:
pCODR 10145
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
2019-05-17